Top ▲
Target has curated data in GtoImmuPdb
Target id: 1871
Nomenclature: tumor necrosis factor receptor 2
Abbreviated Name: TNFR2
Systematic Nomenclature: TNFRSF1B
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 461 | 1p36.22 | TNFRSF1B | TNF receptor superfamily member 1B | |
Mouse | 1 | 474 | 4 78.17 cM | Tnfrsf1b | tumor necrosis factor receptor superfamily, member 1b | |
Rat | 1 | 474 | 5q36 | Tnfrsf1b | TNF receptor superfamily member 1B |
Previous and Unofficial Names |
CD120b | TNF-R2 | p75 TNFR | TNFalpha-R2 | TNF-R75 | TNFRII | tumor necrosis factor receptor superfamily, member 1B | tumor necrosis factor receptor superfamily |
Database Links | |
Alphafold | P20333 (Hs), P25119 (Mm), Q80WY6 (Rn) |
ChEMBL Target | CHEMBL1250356 (Hs) |
Ensembl Gene | ENSG00000028137 (Hs), ENSMUSG00000028599 (Mm), ENSRNOG00000016575 (Rn) |
Entrez Gene | 7133 (Hs), 21938 (Mm), 156767 (Rn) |
Human Protein Atlas | ENSG00000028137 (Hs) |
KEGG Gene | hsa:7133 (Hs), mmu:21938 (Mm), rno:156767 (Rn) |
OMIM | 191191 (Hs) |
Pharos | P20333 (Hs) |
UniProtKB | P20333 (Hs), P25119 (Mm), Q80WY6 (Rn) |
Wikipedia | TNFRSF1B (Hs) |
Natural/Endogenous Ligands |
lymphotoxin-α {Sp: Human} |
tumour necrosis factor membrane form {Sp: Human} |
Adaptor proteins (Human) |
TRAF1, TRAF2, TRAF5 |
Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
TNFR2 is a receptor for lymphotoxin-α, and the membrane form of tumour necrosis factor (TNF). It plays a variety of important roles in immune system development and regulation [4-5], mediating immune suppression and tissue regeneration. It achieves immune suppression by influencing activation and proliferation of TNFR2-expressing Treg cells [2]. TNFR2 on Treg cells in the tumour microenvironment and on tumour cells is considered to be a therapeutically tractable target for novel immuno-oncology agents [7]. TNFR2 antagonistic antibodies [3] have the potential to reduce Treg and cancer cell activation and/or proliferation [1,6], and concomittantly promote proliferation of Teff cells, further contributing to immune system-mediated destruction of tumour cells. |
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
1. Chen X, Oppenheim JJ. (2017) Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Sci Signal, 10 (462). [PMID:28096506]
2. Chen X, Wu X, Zhou Q, Howard OM, Netea MG, Oppenheim JJ. (2013) TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol, 190 (3): 1076-84. [PMID:23277487]
3. Fischer R, Marsal J, Guttà C, Eisler SA, Peters N, Bethea JR, Pfizenmaier K, Kontermann RE. (2017) Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Sci Rep, 7 (1): 6607. [PMID:28747780]
4. Gubernatorova EO, Tumanov AV. (2016) Tumor Necrosis Factor and Lymphotoxin in Regulation of Intestinal Inflammation. Biochemistry Mosc, 81 (11): 1309-1325. [PMID:27914457]
5. Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG. (1999) Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med, 189 (2): 403-12. [PMID:9892622]
6. Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, Defusco A, Plager S, Warden S, Huang D et al.. (2017) Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal, 10 (462). [PMID:28096513]
7. Vanamee ÉS, Faustman DL. (2017) TNFR2: A Novel Target for Cancer Immunotherapy. Trends Mol Med, 23 (11): 1037-1046. [PMID:29032004]